Log in

NASDAQ:BSTCBioSpecifics Technologies Stock Price, Forecast & News

+0.70 (+1.09 %)
(As of 08/4/2020 04:00 PM ET)
Today's Range
Now: $65.01
50-Day Range
MA: $62.93
52-Week Range
Now: $65.01
Volume46,740 shs
Average Volume31,816 shs
Market Capitalization$477.17 million
P/E Ratio19.52
Dividend YieldN/A
BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX or Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, and human lipoma, as well as uterine fibroids. In addition, the company engages in the development of other clinical indications for which collagenase injection has been tested, such as keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. BioSpecifics Technologies Corp. has a development and license agreement with Endo Global Ventures. The company was founded in 1957 and is headquartered in Lynbrook, New York.
Read More
BioSpecifics Technologies logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.80 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:BSTC



Sales & Book Value

Annual Sales$38.19 million
Cash Flow$3.41 per share
Book Value$16.96 per share


Net Income$24.47 million


Market Cap$477.17 million
Next Earnings Date8/14/2020 (Estimated)
OptionableNot Optionable
+0.70 (+1.09 %)
(As of 08/4/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BSTC News and Ratings via Email

Sign-up to receive the latest news and ratings for BSTC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

BioSpecifics Technologies (NASDAQ:BSTC) Frequently Asked Questions

How has BioSpecifics Technologies' stock been impacted by COVID-19 (Coronavirus)?

BioSpecifics Technologies' stock was trading at $55.93 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BSTC shares have increased by 16.2% and is now trading at $65.01.
View which stocks have been most impacted by Coronavirus

Do Wall Street analysts recommend investors buy shares of BioSpecifics Technologies?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioSpecifics Technologies in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for BioSpecifics Technologies

When is BioSpecifics Technologies' next earnings date?

BioSpecifics Technologies is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020.
View our earnings forecast for BioSpecifics Technologies

How were BioSpecifics Technologies' earnings last quarter?

BioSpecifics Technologies Corp. (NASDAQ:BSTC) announced its earnings results on Monday, May, 11th. The biopharmaceutical company reported $0.73 EPS for the quarter, missing the Zacks' consensus estimate of $0.76 by $0.03. The biopharmaceutical company earned $9.67 million during the quarter, compared to the consensus estimate of $9.20 million. BioSpecifics Technologies had a net margin of 61.80% and a return on equity of 21.37%.
View BioSpecifics Technologies' earnings history

What price target have analysts set for BSTC?

1 Wall Street analysts have issued 12 month price targets for BioSpecifics Technologies' stock. Their forecasts range from $100.00 to $100.00. On average, they expect BioSpecifics Technologies' share price to reach $100.00 in the next twelve months. This suggests a possible upside of 53.8% from the stock's current price.
View analysts' price targets for BioSpecifics Technologies

Has BioSpecifics Technologies been receiving favorable news coverage?

News headlines about BSTC stock have trended somewhat negative recently, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. BioSpecifics Technologies earned a coverage optimism score of -1.0 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the stock's share price in the near term.
View the latest news about BioSpecifics Technologies

Are investors shorting BioSpecifics Technologies?

BioSpecifics Technologies saw a decrease in short interest in the month of July. As of July 15th, there was short interest totaling 282,400 shares, a decrease of 5.6% from the June 30th total of 299,000 shares. Based on an average daily volume of 37,100 shares, the days-to-cover ratio is presently 7.6 days. Approximately 4.9% of the company's stock are short sold.
View BioSpecifics Technologies' Current Options Chain

Who are some of BioSpecifics Technologies' key competitors?

What other stocks do shareholders of BioSpecifics Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioSpecifics Technologies investors own include AbbVie (ABBV), Biogen (BIIB), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Alibaba Group (BABA), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), AT&T (T), Intel (INTC) and Johnson & Johnson (JNJ).

Who are BioSpecifics Technologies' key executives?

BioSpecifics Technologies' management team includes the following people:
  • Dr. Ronald Law J.D., Ph.D., Interim Principal Exec. Officer (Age 66)
  • Mr. Patrick M. Caldwell, Interim Principal Financial Officer (Age 57)
  • Carl A. Valenstein, Corp. Sec.

What is BioSpecifics Technologies' stock symbol?

BioSpecifics Technologies trades on the NASDAQ under the ticker symbol "BSTC."

Who are BioSpecifics Technologies' major shareholders?

BioSpecifics Technologies' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Cadence Capital Management LLC (0.48%), Cambridge Investment Research Advisors Inc. (0.17%), Strs Ohio (0.11%), James Investment Research Inc. (0.09%), UBS Group AG (0.05%) and SG Americas Securities LLC (0.05%). Company insiders that own BioSpecifics Technologies stock include Jennifer M Chao, Mark N Wegman, Of Edwin H Wegman Estate, Patrick M Caldwell, Paul Gitman, Thomas Wegman and Toby Wegman.
View institutional ownership trends for BioSpecifics Technologies

Which institutional investors are selling BioSpecifics Technologies stock?

BSTC stock was sold by a variety of institutional investors in the last quarter, including Cadence Capital Management LLC, Nisa Investment Advisors LLC, Cambridge Investment Research Advisors Inc., and UBS Group AG.
View insider buying and selling activity for BioSpecifics Technologies

Which institutional investors are buying BioSpecifics Technologies stock?

BSTC stock was acquired by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, James Investment Research Inc., Strs Ohio, Denali Advisors LLC, and Emerald Advisers LLC.
View insider buying and selling activity for BioSpecifics Technologies

How do I buy shares of BioSpecifics Technologies?

Shares of BSTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BioSpecifics Technologies' stock price today?

One share of BSTC stock can currently be purchased for approximately $65.01.

How big of a company is BioSpecifics Technologies?

BioSpecifics Technologies has a market capitalization of $477.17 million and generates $38.19 million in revenue each year. The biopharmaceutical company earns $24.47 million in net income (profit) each year or $3.33 on an earnings per share basis. BioSpecifics Technologies employs 6 workers across the globe.

What is BioSpecifics Technologies' official website?

The official website for BioSpecifics Technologies is www.biospecifics.com.

How can I contact BioSpecifics Technologies?

BioSpecifics Technologies' mailing address is 2 Righter Parkway Suite 200, Wilmington DE, 19803. The biopharmaceutical company can be reached via phone at 302-842-8450 or via email at [email protected]

This page was last updated on 8/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.